High-contrast PET of melanoma using 18F-MEL050, a selective probe for melanin with predominantly renal clearance

Journal of Nuclear Medicine

Volumn 51, Issue 3, 2010, Pages 441-447

  Denoyer, Delphine ^a   Greguric, Ivan ^b   Roselt, Peter ^a   Neels, Oliver C ^a   Aide, Nicolas ^a   Taylor, Stephen R ^b   Katsifis, Andrew ^b   Dorow, Donna S ^a   Hicks, Rodney J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Fluoronicotinamide analogue; High resolution autoradiography; Melanoma imaging; PET CT; Small animal PET

Indexed keywords

6 FLUORO N[2 (DIETHYLAMINO)ETHYL]PYRIDINE 3 CARBOXAMIDE FLUORINE F 18; FLUORODEOXYGLUCOSE F 18; MELANIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; N (2 (DIETHYLAMINO)ETHYL) 6 FLUORONICOTINAMIDE; N-(2-(DIETHYLAMINO)ETHYL)-6-FLUORONICOTINAMIDE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

AMELANOTIC MELANOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; KIDNEY CLEARANCE; LUNG METASTASIS; METASTASIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ALLOTRANSPLANTATION; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; ENZYME SPECIFICITY; HUMAN; KIDNEY; MELANOMA; METABOLISM; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; TUMOR CELL LINE; WHOLE BODY IMAGING;

ANIMALS; AUTORADIOGRAPHY; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CONTRAST MEDIA; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY; MELANINS; MELANOMA; MICE; NEOPLASM METASTASIS; NIACINAMIDE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; SUBSTRATE SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HOMOLOGOUS; WHOLE BODY IMAGING;

EID: 77950361631     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.070060     Document Type: Article

References (37)

1. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983;1:126-134.
2. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-149.
3. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117-127.
4. Ollila DW, Caudle AS. Surgical management of distant metastases. Surg Oncol Clin N Am. 2006;15:385-398.
5. Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology. 2008;249:836-844.
6. Veit-Haibach P, Vogt FM, Jablonka R, et al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging. 2009;36:910-918.
7. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in earlystage cutaneous melanoma. Cancer. 2005;104:570-579. (Pubitemid 41022815)
8. Mittra E, Quon A. Positron emission tomography/computed tomography: the current technology and applications. Radiol Clin North Am. 2009;47:147-160.
9. 18F-FDG in oncology. J Nucl Med Technol. 2002;30:3-9.
10. Sobal G, Rodrigues M, Sinzinger H. Radioiodinated methylene blue: a promising agent for melanoma scintigraphy - labelling, stability and in vitro uptake by melanoma cells. Anticancer Res. 2008;28:3691-3696.
11. Beatovic S, Obradovic V, Latkovic Z, Jaksic E. Diagnosis and follow up of primary ocular melanoma by radioimmunoscintigraphy. J BUON. 2004;9:299-302. (Pubitemid 40360807)
12. 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci USA. 2007;104:17489-17493.
13. 123I-IMP SPECT. J Nucl Med. 2006;47:404-409.
14. 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide. Nucl Med Biol. 2009;36:267-276.
15. Miao Y, Figueroa SD, Fisher DR, et al. 203Pb-labeled a-melanocyte- stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med. 2008;49:823-829. (Pubitemid 351717549)
16. Chezal JM, Papon J, Labarre P, et al. Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem. 2008;51:3133-3144. (Pubitemid 351821874)
17. Pham TQ, Greguric I, Liu X, et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem. 2007;50:3561-3572. (Pubitemid 47195463)
18. Moins N, D'Incan M, Bonafous J, et al. 123I-N-(2-diethylaminoethyl)-2- iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol Imaging. 2002;29:1478-1484. (Pubitemid 35232050)
19. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma [in French]. J Fr Ophtalmol. 2004;27:34-39.
20. 123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma. Acta Ophthalmol Scand. 1998;76:56-61.
21. Larisch R, Schulte KW, Vosberg H, Ruzicka T, Muller-Gartner HW. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med. 1998;39:996-1001. (Pubitemid 28270114)
22. 123I-MEL037, for malignant melanoma. J Nucl Med. 2007;48:1348-1356.
23. 18F]-DAFBA): a novel potential PET probe to image melanoma tumors. Bioconjug Chem. 2009;20:583-590.
24. 18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. J Med Chem. 2009;52:5299-5302.
25. Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging. 2007;34:532-540. (Pubitemid 46426995)
26. Chiang S, Cardi C, Matej S, et al. Clinical validation of fully 3-D versus 2.5-D RAMLA reconstruction on the Philips-ADAC CPET PET scanner. Nucl Med Commun. 2004;25:1103-1107. (Pubitemid 39488942)
27. Tanaka E, Kudo H. Subset-dependent relaxation in block-iterative algorithms for image reconstruction in emission tomography. Phys Med Biol. 2003;48:1405-1422. (Pubitemid 36700473)
28. Michelot JM, Moreau MF, Veyre AJ, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2- diethylaminoethyl4-iodobenzamide). J Nucl Med. 1993;34:1260-1266. (Pubitemid 23230353)
29. Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet Oncol. 2009;10:516-521.
30. 2), an imaging agent for melanoma staging: relation to pigmentation. Nucl Med Biol. 2005;32:451-458.
31. Chehade F, De Labriolle-Vaylet C, Michelot J, et al. Distribution of I-BZA (N-2-diethylaminoethyl-4-iodobenzamide) in grafted melanoma and normal skin: a study by secondary ion mass spectroscopy. Cell Mol Biol (Noisy-le-grand). 2001;47:529-534.
32. Verhoeff NP, Sokole EB, Stabin M, et al. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med. 1993;20:747-752. (Pubitemid 23315288)
33. Ho Shon IA, Chung DK, Saw RP, Thompson JF. Imaging in cutaneous melanoma. Nucl Med Commun. 2008;29:847-876.
34. Li TR, Tian JH, Wang H, Chen ZQ, Zhao CL. Pitfalls in positron emission tomography/computed tomography imaging: causes and their classifications. Chin Med Sci J. 2009;24:12-19.
35. 18F-2-deoxy-2-fluoroglucose accumulation in the stomach on positron emission tomography. Ann Nucl Med. 2009;23:391-397.
36. Ren G, Miao Z, Liu H, et al. Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med. 2009;50:1692-1699.
37. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol. 2007;34:546-554. (Pubitemid 350236312)